Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluoxetine hydrochloride, quantity: 22.35 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; shellac; ethanol absolute; iron oxide black; butan-1-ol; isopropyl alcohol; propylene glycol; purified water; titanium dioxide; brilliant blue fcf; iron oxide yellow; gelatin; sodium lauryl sulfate - treatment of major depression. treatment of obsessive compulsive disorder. treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.,the essential features of pmdd, according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluoxetine hydrochloride, quantity: 22.35 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; shellac; ethanol absolute; iron oxide black; butan-1-ol; isopropyl alcohol; propylene glycol; purified water; titanium dioxide; brilliant blue fcf; iron oxide yellow; gelatin; sodium lauryl sulfate - treatment of major depression. treatment of obsessive compulsive disorder. treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.,the essential features of pmdd, according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.

Canada - English - Health Canada

criterion sciences - dextrose - liquid - 5g - dextrose 5g - diabetes mellitus

Canada - English - Health Canada

criterion sciences - dextrose - liquid - 10g - dextrose 10g - diabetes mellitus

Canada - English - Health Canada

criterion sciences - dextrose - liquid - 7.5g - dextrose 7.5g - diabetes mellitus

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - sertraline hydrochloride, quantity: 112 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hyprolose; sodium starch glycollate; calcium hydrogen phosphate; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - adults: sertraline-lapl tablets are indicated for the treatment of major depression. sertraline-lapl tablets are indicated for the treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - sertraline hydrochloride, quantity: 56 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; sodium starch glycollate; calcium hydrogen phosphate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - adults: sertraline-lapl tablets are indicated for the treatment of major depression. sertraline-lapl tablets are indicated for the treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 114.3 mg (equivalent: atomoxetine, qty 100 mg) - capsule, hard - excipient ingredients: iron oxide red; gelatin; iron oxide yellow; dimeticone 350; sodium lauryl sulfate; pregelatinised maize starch; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - atomoxetine hydrochloride, quantity: 91.42 mg (equivalent: atomoxetine, qty 80 mg) - capsule, hard - excipient ingredients: iron oxide red; sodium lauryl sulfate; gelatin; iron oxide yellow; titanium dioxide; dimeticone 350; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - strattera is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sertraline hydrochloride, quantity: 111.8 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; methylcellulose; magnesium stearate; hypromellose; hyprolose; titanium dioxide; iron oxide yellow; colloidal anhydrous silica; macrogol 8000 - sertraline is indicated in adults for the treatment of 1) major depression; 2) premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.